iiinova — where your digital self keeps evolving

Unidad de ETV HGUGM @etvgregorio.bsky.social · 11/06/2026

Wrapped up a fantastic day at the VII Forum of Updates in VTE! Huge thanks to our incredible speakers for sharing such insightful perspectives, and to everyone who attended and made the discussions so engaging. #VTE #MedSky #Thrombosis #InternalMedicine #MedEd @luciaordieres.bsky.social

000

Unidad de ETV HGUGM @etvgregorio.bsky.social · 23/06/2025

The struggle is real. So much uncertainty for both clinicians and patients! We need further research on this topic to provide better, accurate #APS diagnosis and improve patients' QoL.

010

Reposted by Unidad de ETV HGUGM

Saskia Middeldorp @middeldorps.bsky.social · 22/06/2025

Dragons’s Den of the highly fruitful www.invent-vte.com netwerk. Collaboration leads to practice-changing trials!! #ISTH2025

042

Unidad de ETV HGUGM @etvgregorio.bsky.social · 09/06/2025

Whenever you see a young male with EN and DVT, always remember to ask about oral&genital ulcers! #VTE #thrombosis #Behçet #IMSky

000

Unidad de ETV HGUGM @etvgregorio.bsky.social · 09/06/2025

This vasculitis may show multiple symptoms. The International Criteria may be helpful in the diagnosis:

100

Unidad de ETV HGUGM @etvgregorio.bsky.social · 09/06/2025

Young male + erythema nodosum (EN) + VTE... Think of Behçet disease!

100

Unidad de ETV HGUGM @etvgregorio.bsky.social · 08/06/2025

What should you absolutely think of if you see a young male with acute DVT of this leg? #Medicine #VTE @luciaordieres.bsky.social

000

Unidad de ETV HGUGM @etvgregorio.bsky.social · 24/05/2025

Most women taking combined contraception who develop VTE state that they have never been informed of the thrombotic risk. Do you tell your patients about the risk of blood clots?

010

Unidad de ETV HGUGM @etvgregorio.bsky.social · 15/04/2025

A recent consensus tries to define the patient with acute PE that would benefit most from Hospital at Home management: authors.elsevier.com/a/1kwL63FTR6... #VTESky #VTE #HospitalAtHome #HemeSky

authors.elsevier.com

000

Unidad de ETV HGUGM @etvgregorio.bsky.social · 10/04/2025

A recent metaanalysis including 22 articles states that: ⌚️ Transient risk factor: 3-6 months of treatment superior to extended therapy. 🛌 Unprovoked VTE or chronic provoking factor: extended therapy is superior to limited.

100

Unidad de ETV HGUGM @etvgregorio.bsky.social · 10/04/2025

When starting anticoagulation for VTE, there are two main points: 🔍 Diagnosis. Here, risk-benefit assessment for anticoagulation must be performed. 🗓️ 3-6 months. Here, one must consider reduced doses vs perhaps withdrawing anticoagulation completely.

100

Unidad de ETV HGUGM @etvgregorio.bsky.social · 04/04/2025

This past two days, we have participated in the #5ForoETV, a national meeting on #VTE. We have presented our studies on early discharge of DVT from the ER, ethnicity in VTE and artificial intelligence. Always wonderful to meet people who love VTE! online.fliphtml5.com/qimqu/kvcd/#...

121

Unidad de ETV HGUGM @etvgregorio.bsky.social · 01/04/2025

Do you use, or plan to, apixaban 2.5 mg in cancer patients with VTE? 👀 #VTE #VTESky #HemeSky #IMSky #apixaban @luciaordieres.bsky.social

000

Unidad de ETV HGUGM @etvgregorio.bsky.social · 01/04/2025

Results: 🫁 Non inferiority for recurrence or mortality. 🩸Less bleeding events with apixaban 2.5 mg. This is a question many of us have asked ourselves when facing cancer patients in our clinical practice, and now we finally have an answer.

100

Unidad de ETV HGUGM @etvgregorio.bsky.social · 01/04/2025

Recently published in @nejm.org, API-CAT: 👯 1766 cancer patients. 🎂 69 years old. 👨‍🦰43.4% men. 🦵 Included, in average, 8 months after VTE. 🗓️ Median follow-up 11.8 months. 💊 Apixaban 2.5 mg vs 5 mg twice daily.

100

Unidad de ETV HGUGM @etvgregorio.bsky.social · 01/04/2025

You might remember the EVE trial (2023): 💊 apixaban 2.5 mg vs 5 mg twice daily in cancer patients with VTE after 6-12 months of treatment. 🩸Primary outcome: bleeding. 🗓️ Follow-up: 12 months. 👯360 patients included in analysis. Shockingly, apixaban 2.5 mg did not reduce bleeding compared to 5 mg.

100

Unidad de ETV HGUGM @etvgregorio.bsky.social · 01/04/2025

API-CAT is finally here! t.co/7g6YSpeWmZ This study really changes clinical practice, let's see why: 🧵

t.co

https://www.nejm.org/doi/full/10.1056/NEJMoa2416112

120

Unidad de ETV HGUGM @etvgregorio.bsky.social · 08/03/2025

❓TUS may pose a management challenge due to the lack of solid evidence. 💊We compared 161 patients treated with DOACs vs VKAs. ⛑️Overall, no differences in major bleeding or recurrences. 🧪DOACs: Pharmacokinetic advantages. 🍺Need to individualize in some populations (liver disease...).

100

Unidad de ETV HGUGM @etvgregorio.bsky.social · 20/02/2025

For those of you who understand Spanish, Dr. Galeano tells us about inferior vena cava filters: youtu.be/qAMIJondzQI

youtu.be

Protocolo Filtro Vena Cava Inferior, Dr. Francisco Galeano

YouTube video by GT Tromboembólica SEMI

000

Reposted by Unidad de ETV HGUGM

The Awkward Yeti @theawkwardyeti.bsky.social · 09/02/2025

Let’s do this Linktr.ee/theawkwardyeti

316618

Reposted by Unidad de ETV HGUGM

STITCHES Medicine - the Best of Medical Research @medicine.stitches.today · 08/02/2025

Continuation of oral anticoagulation during TAVI led to higher bleeding rates without reducing major complications compared to interruption. by van Ginkel DJ, Bor WL (...) Schotborgh CE et 11 al. in N Engl J Med #MedSky 📖 read the article: www.nejm.org/doi/10.1056/NEJMoa2407…

032

Unidad de ETV HGUGM @etvgregorio.bsky.social · 03/02/2025

Now, the patient had a personal history of two miscarriages (< week 20) and pericarditis 5 years prior. Does that change your judgment? Genuinely curious what you think! #VTE #HemeSky #Thrombosis #IMSky #MedSky #ClinicalCase #VTESky

000

Unidad de ETV HGUGM @etvgregorio.bsky.social · 03/02/2025

This morning at the ward: Female, 40 years old. PE one year prior, non-provoked. DVT six months prior (under vitK inhibitors). Treatment remained the same. MI two months prior, changed to DOAC. Currently admitted due to PE (incidental finding). What would you do in this case? 1/2

100

Unidad de ETV HGUGM @etvgregorio.bsky.social · 29/12/2024

💬 How do you approach CRT in your clinical practice? Are current guidelines sufficient, or do you see gaps in evidence? Please let us know what you think! #Thrombosis #MedicalResearch #Medicine #VTESky #HemeSky

000

Unidad de ETV HGUGM @etvgregorio.bsky.social · 29/12/2024

🌍 Need for further research in CRT, particularly regarding: 💊 Optimal anticoagulant regimens. 🗓️ Duration of therapy tailored to patient characteristics. 💉 Prophylaxis for selected populations.

100

Unidad de ETV HGUGM @etvgregorio.bsky.social · 29/12/2024

⚠️ Up to 50% of CRT cases are asymptomatic, making routine monitoring critical in high-risk patients, particularly those with cancer or long-term indwelling catheters.

100

Unidad de ETV HGUGM @etvgregorio.bsky.social · 29/12/2024

🛡️ Prevention Strategies: 🔍 Careful evaluation of catheter necessity and type. 📍 Optimal placement at the superior vena cava-right atrium junction. 💉 Anticoagulant locking solutions (e.g., heparin, citrate). 🛟 In high-risk populations, carefully consider thromboprophylaxis with LMWH or DOACs.

100

Unidad de ETV HGUGM @etvgregorio.bsky.social · 29/12/2024

💊 Treatment: Anticoagulation: LMWH or DOACs are first-line therapies. Catheter removal is indicated only in select cases, such as unresolved thrombosis or infection. Thrombolysis and catheter-directed interventions are options for severe presentations.

100

Unidad de ETV HGUGM @etvgregorio.bsky.social · 29/12/2024

🔬 Diagnostic Approach: 🩻 Doppler Ultrasound: Sensitivity 91%, specificity 93%, though clavicle anatomy may limit visualization of subclavian veins. 🤔 Advanced imaging (CTA, MRI) is reserved for high clinical suspicion or inconclusive ultrasound findings.

100

Unidad de ETV HGUGM @etvgregorio.bsky.social · 29/12/2024

🩺 Clinical Presentation: 💪 Swelling, pain, or venous distension in the affected limb. 💉 Catheter dysfunction (e.g., inability to aspirate). 🫁 Severe cases may progress to pulmonary embolism (PE) or superior vena cava syndrome (SVCS).

100

Unidad de ETV HGUGM @etvgregorio.bsky.social · 29/12/2024

🚨 Key Risk Factors: 🧑Patient-related: Cancer, history of venous thromboembolism (VTE), infections, and inflammatory states. 🚦Catheter-specific: Larger gauge, multi-lumen designs, and improper placement. These insights are crucial for stratifying at-risk populations.

100

Unidad de ETV HGUGM @etvgregorio.bsky.social · 29/12/2024

🔍 CRT accounts for 80–90% of upper extremity deep vein thrombosis (UEDVT) cases and is often linked to central venous catheters and implantable devices. Understanding its risk factors and management is critical for optimizing patient outcomes. 👇

100

Unidad de ETV HGUGM @etvgregorio.bsky.social · 29/12/2024

📢 Catheter-Related Thrombosis (CRT): A common yet underrecognized complication associated with intravascular devices. 🧵This thread explores the latest evidence on pathophysiology, diagnosis, and treatment strategies. #Thrombosis #MedicalResearch

110

Reposted by Unidad de ETV HGUGM

RPTH @rpth.bsky.social · 18/12/2024

🦠 Thromboprophylaxis in COVID-19 outpatients: Modest reduction in VTE risk (NNT: 174) but no impact on death or hospitalization. 🏥 Findings suggest routine use is not warranted in this population.

buff.ly

011

Unidad de ETV HGUGM @etvgregorio.bsky.social · 12/12/2024

Although it is a small, single centre study, it reflects the actual reality of APS in our daily practice, which is sometimes far from that of the clinical studies. Hope you enjoyed it! #MedResearch #SkyMed #SkyVTE #Medicine @luciaordieres.bsky.social

000

Unidad de ETV HGUGM @etvgregorio.bsky.social · 12/12/2024

📌 DOACs showed similar safety and efficacy to VKAs in APS patients with VTE and may be a viable alternative in less severe profiles. Larger, randomized trials are essential to increase available evidence in diverse APS profiles.

100

Unidad de ETV HGUGM @etvgregorio.bsky.social · 12/12/2024

📊 Thrombotic recurrence (either arterial or venous): 16.1% (VKAs) vs 15.8% (DOACs), OR 1.01 (IC 95% 0,19-5,46). 🩸 Major bleeding: 6.45% (VKAs) vs 0% (DOACs), OR 1,09 (IC 95% 0,14-8,52). No strokes 🧠, only one miocardial infarction in each group 🫀. No significant differences between groups.

100

Unidad de ETV HGUGM @etvgregorio.bsky.social · 12/12/2024

🔬 Our study follows 50 patients with APS and VTE, comparing treatment with DOACs (19 patients) vs VKAs (31 patients). One big difference: only 18% were triple positive, compared to nearly 60% in previous studies.

100

Unidad de ETV HGUGM @etvgregorio.bsky.social · 12/12/2024

Previous research shows more arterial events (especially strokes 🧠) in APS patients taking DOACs vs VKA. A recent review advises against using DOACS in APS. The evidence seems clear in triple positive APS, but not strong enough in single or double positive APS. shorturl.at/pkuUA

100

Unidad de ETV HGUGM @etvgregorio.bsky.social · 12/12/2024

Really excited to share our real life experience with DOACs in patients with APS: a short 🧵 (You can find the entire article here: authors.elsevier.com/a/1kEg-5t5920fO)

authors.elsevier.com

100

Reposted by Unidad de ETV HGUGM

Nicolas Gendron @gendronn.bsky.social · 29/11/2024

🤓 Type of D-dimer assay determines the diagnostic yield of CTPA in patients suspected for PE - @rpth.bsky.social ➡️Hospitals using the Roche Tinaquant assay ordered 21% fewer CTPAs and had an 7% higher positivity rate compared to those using the Siemens www.rpthjournal.org/article/S247...

rpthjournal.org

DEFINE_ME

011